Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, it operated 4,171 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Fresenius Medical Care AG & Co. KGaA Stock Performance
Shares of NYSE:FMS remained flat at $18.66 during mid-day trading on Tuesday. 578,219 shares of the company traded hands, compared to its average volume of 628,774. The company has a current ratio of 1.18, a quick ratio of 0.85 and a debt-to-equity ratio of 0.47. The stock has a market capitalization of $10.94 billion, a P/E ratio of 11.89, a PEG ratio of 0.92 and a beta of 1.03. Fresenius Medical Care AG & Co. KGaA has a fifty-two week low of $18.16 and a fifty-two week high of $40.85. The firm's 50-day simple moving average is $23.89 and its 200 day simple moving average is $29.38.
Wall Street Analysts Forecast Growth
Several research firms have recently issued reports on FMS. DZ Bank cut shares of Fresenius Medical Care AG & Co. KGaA from a "buy" rating to a "hold" rating in a report on Friday, July 29th. Jefferies Financial Group upgraded shares of Fresenius Medical Care AG & Co. KGaA from an "underperform" rating to a "buy" rating and increased their price objective for the company from $30.30 to $33.70 in a report on Monday, June 27th. UBS Group cut shares of Fresenius Medical Care AG & Co. KGaA from a "buy" rating to a "neutral" rating in a report on Friday, July 29th. StockNews.com cut shares of Fresenius Medical Care AG & Co. KGaA from a "strong-buy" rating to a "buy" rating in a report on Friday, July 15th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Fresenius Medical Care AG & Co. KGaA from €51.00 ($52.04) to €23.00 ($23.47) in a report on Monday, August 1st. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, Fresenius Medical Care AG & Co. KGaA presently has an average rating of "Hold" and an average price target of $49.01.